Thomas A Rasmussen
Overview
Explore the profile of Thomas A Rasmussen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pascoe R, Kim Y, Rhodes A, Ong J, Tumpach C, Gubser C, et al.
J Virol
. 2025 Feb;
:e0167624.
PMID: 39902962
HIV persists in people living with HIV (PLHIV) on antiretroviral therapy (ART) in long-lived and proliferating latently infected CD4+ T cells that selectively express pro-survival proteins, including the zinc finger...
2.
Gubser C, Pascoe R, Trautmann L, Rasmussen T, Lewin S
STAR Protoc
. 2024 Aug;
5(3):103231.
PMID: 39116199
Here, we present a protocol to evaluate the killing capacity and functional profile of human HIV-specific CD8 T cells. We describe steps for culturing peripheral blood mononuclear cells (PBMCs) from...
3.
Gubser C, Pascoe R, Chang J, Chiu C, Solomon A, Cao R, et al.
iScience
. 2023 Nov;
26(11):108165.
PMID: 38026168
Glucocorticoid-induced tumor necrosis factor related protein (GITR) is a co-stimulatory immune checkpoint molecule constitutively expressed on regulatory T cells (T) and on activated T conventional cells (T). In blood collected...
4.
Gunst J, Goonetilleke N, Rasmussen T, Sogaard O
J Virus Erad
. 2023 Sep;
9(3):100347.
PMID: 37767312
Immunomodulating agents are substances that modify the host immune responses in diseases such as infections, autoimmune conditions and cancers. Immunomodulators can be divided into two main groups: 1) immunostimulators that...
5.
Pitman M, Meagher N, Price D, Rhodes A, Chang J, Scher B, et al.
J Virus Erad
. 2023 Sep;
9(3):100345.
PMID: 37753336
Introduction: Antiretroviral therapy for people living with HIV-1 must be taken lifelong due to the persistence of latent virus in long-lived and proliferating CD4 T cells. Vitamin D is a...
6.
Gunst J, Hojen J, Pahus M, Rosas-Umbert M, Stiksrud B, McMahon J, et al.
Nat Med
. 2023 Sep;
29(10):2547-2558.
PMID: 37696935
Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double-blinded trial, 43 people (85% males)...
7.
Chiu C, Schou M, McMahon J, Deeks S, Fromentin R, Chomont N, et al.
Front Immunol
. 2023 Apr;
14:1123342.
PMID: 37056754
Introduction: In people with HIV (PWH) both off and on antiretroviral therapy (ART), the expression of immune checkpoint (IC) proteins is elevated on the surface of total and HIV-specific T-cells,...
8.
Fisher K, Schlub T, Boyer Z, Rasmussen T, Rhodes A, Hoh R, et al.
Front Immunol
. 2023 Feb;
14:1064346.
PMID: 36776833
Introduction: HIV-1 persists in resting CD4 T-cells despite antiretroviral therapy (ART). Determining the cell surface markers that enrich for genetically-intact HIV-1 genomes is vital in developing targeted curative strategies. Previous...
9.
Rasmussen L, Lebech A, Ovrehus A, Poulsen B, Christensen H, Nielsen H, et al.
Br J Clin Pharmacol
. 2022 Dec;
89(6):1820-1833.
PMID: 36519217
Aims: To evaluate the experience with use of sotrovimab following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in high-risk groups. Methods: In a nationwide, population-based cohort study, we identified all...
10.
Rasmussen T, Zerbato J, Rhodes A, Tumpach C, Dantanarayana A, McMahon J, et al.
Cell Rep Med
. 2022 Oct;
3(10):100766.
PMID: 36198308
Programmed cell death 1 (PD1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) suppress CD4 T cell activation and may promote latent HIV infection. By performing leukapheresis (n = 21) and...